This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Daxas
  • /
  • Effect of Roflumilast on Exacerbation Rate in Pati...
Clinical trial

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Read time: 1 mins
Last updated:1st Feb 2006

The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will last up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast.


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study
Enrollment: 1523
Study Start Date: February 2006
Study Completion Date: September 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)

Arms:
- Active Comparator:
Roflumilast
- Placebo Comparator: Placebo

Category Value
Study start date 2006-02-01

View full details